Cytori Therapeutics Inc. (NASDAQ:CYTX) confirmed that two Japanese regenerative medicine laws which went into effect on November 25 2014 remove regulatory uncertainties and provide a clear path for the Company to commercialize and market Cytori Cell Therapy™ and its Celution® System under the Company’s existing and planned regulatory approvals. Cytori Therapeutics, Inc. (NASDAQ:CYTX) in last trading activity increased 5.16% to close at $0.44. Company weekly performance is 0.50% while its quarterly performance stands at -65.07%. Cytori Therapeutics, Inc. (NASDAQ:CYTX) is -87.32% away from its 52 week high.
Gilead Sciences (NASDAQ:GILD) EVP Paul Rutherford Carter sold 2,000 shares of Gilead Sciences stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $100.02, for a total value of $200,040.00. Following the sale, the executive vice president now directly owns 34,308 shares in the company, valued at approximately $3,431,486.On last trading day Gilead Sciences Inc. (NASDAQ:GILD) increased 0.93% to close at $101.82. Its volatility for the week is 2.20% while volatility for the month is 2.60%. GILD’s sales growth for past 5 years was 16.00% and its EPS growth for past 5 years was 11.90%. Gilead Sciences Inc. (NASDAQ:GILD) monthly performance is -7.20%.
Parsley Energy (NYSE:PE) has been given a consensus rating of “Buy” by the fourteen brokerages that are covering the company, Analyst Ratings Network.com reports. One analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $26.83. On last trading day Parsley Energy, Inc. (NYSE:PE) moved down -4.23% to close at $13.14. Its volatility for the week is 9.46% while volatility for the month is 6.22%. Parsley Energy, Inc. (NYSE:PE) monthly performance is -15.01%.
Cherry Hill Mortgage Investment Corporation (NYSE:CHMI) on 12 November reported reported GAAP net income consisted of the following: $5.1 million of net interest income, a net realized gain of $48,000 on the RMBS portfolio, a net realized loss on derivatives of $1.0 million, a net unrealized gain on derivatives of $2.0 million, a net unrealized loss of $2.1 million on the Excess MSR portfolio due to market valuation adjustments, and general and administrative expenses and management fees paid to Cherry Hill’s external manager in the aggregate amount of approximately $1.3 million. Cherry Hill Mortgage Investment Corporation (NYSE:CHMI) has 0.10% insider ownership while its institutional ownership stands at 55.70%. In last trading activity company’s stock closed at $18.56.
PharMerica Corporation (NYSE:PMC) on 6 November reported Net income for the third quarter of 2014 was $8.5 million, or $0.28 diluted earnings per share, compared to a net loss of $6.2 million, or $0.21 diluted loss per share, for the same period in 2013. During the third quarter of 2014 the Company refinanced its debt resulting in a loss on extinguishment of debt of $4.3 million. The net loss in the third quarter of 2013 was primarily attributable to the recording of a $17.0 million reserve associated with various government inquiries and litigations. Adjusted diluted earnings per share was $0.45 in the third quarter of 2014 compared to $0.49 in the third quarter of 2013.On Thursday shares of PharMerica Corporation (NYSE:PMC) closed at $20.75. Company’s sales growth for last 5 years was -2.00% and EPS growth for next 5 years is recorded as 10.00%.